Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
InMode Ltd is a medical devices business based in the US. InMode shares (INMD) are listed on the NASDAQ and all prices are listed in US Dollars. InMode employs 311 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$171.05|
|52-week range||$33.92 - $146.73|
|50-day moving average||$121.98|
|200-day moving average||$94.48|
|Wall St. target price||$123.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.99|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||19.89%|
|1 month (2021-08-25)||37.80%|
|3 months (2021-06-25)||76.92%|
|6 months (2021-03-25)||152.66%|
|1 year (2020-09-25)||373.95%|
|2 years (2019-09-25)||533.05%|
|3 years (2018-09-21)||N/A|
|5 years (2016-09-21)||N/A|
Valuing InMode stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of InMode's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
InMode's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, InMode shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
InMode's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3325. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into InMode's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
InMode's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $127.5 million.
The EBITDA is a measure of a InMode's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$287.8 million|
|Operating margin TTM||44.15%|
|Gross profit TTM||$175.3 million|
|Return on assets TTM||25.57%|
|Return on equity TTM||47.59%|
|Market capitalisation||$5.4 billion|
TTM: trailing 12 months
There are currently 1.9 million InMode shares held short by investors – that's known as InMode's "short interest". This figure is 12% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting InMode shares can be evaluated.
InMode's "short interest ratio" (SIR) is the quantity of InMode shares currently shorted divided by the average quantity of InMode shares traded daily (recently around 792706.69456067). InMode's SIR currently stands at 2.39. In other words for every 100,000 InMode shares traded daily on the market, roughly 2390 shares are currently held short.
However InMode's short interest can also be evaluated against the total number of InMode shares, or, against the total number of tradable InMode shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InMode's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 InMode shares in existence, roughly 40 shares are currently held short) or 0.0586% of the tradable shares (for every 100,000 tradable InMode shares, roughly 59 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InMode.
Find out more about how you can short InMode stock.
We're not expecting InMode to pay a dividend over the next 12 months.
Over the last 12 months, InMode's shares have ranged in value from as little as $33.92 up to $146.7325. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMode's is 1.8793. This would suggest that InMode's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.